A.G.P./Alliance Global Partners

590 Madison Avenue

New York, NY 10022

  

September 8, 2022

 

VIA EDGAR

 

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, NE

Washington, D.C. 20549

 

Attn:  Joshua Gorsky

 

Re: XORTX Therapeutics Inc.
  Registration Statement on Form F-1
  File No. 333-267328
  Request for Acceleration

 

Ladies and Gentlemen:

 

A.G.P./Alliance Global Partners (“A.G.P.”), as underwriter for the referenced offering, hereby concurs in the request by XORTX Therapeutics Inc. that the effective date of the above-referenced registration statement be accelerated to 4:30 p.m., Eastern Time, on September 12, 2022, or as soon as practicable thereafter. A.G.P. affirms that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.

 

Pursuant to Rule 460 under the Act, please be advised that A.G.P. will take reasonable steps to secure adequate distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.

 

A.G.P. has been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.

 

[Signature page follows]

 

  Very truly yours,
   
  A.G.P./Alliance Global Partners
   
  By: /s/Thomas J. Higgins
  Name: Thomas J. Higgins
  Title: Managing Director, Investment Banking